After 20 years of technology improvements, only one antisense drug is on the market: Vitravene (fomivirsen), developed by Isis Pharmaceuticals (Carlsbad, CA, USA) and approved by the US Food and Drug ...

For decades, antisense technology promised to transform the pharmaceutical industry. That moment has now arrived. Dr. Stanley Crooke, a pioneer in the field, explains what’s next. This article was ...

People around the globe suffer from a myriad of rare diseases, many of which have no cure or limited treatment options. Many patients have been living without hope of a significant improvement in ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

In November, Isis Pharmaceuticals (Carlsbad, CA) announced the departure of its longstanding partner, Novartis Pharmaceuticals (Basel, Switzerland), leaving the small biotech company to underwrite ...

CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with ION541 ...

When the director of research at Cold Spring Harbor Laboratory examined his first specimen of cells treated with an experimental breast cancer therapy, he was stunned. David Spector is a seasoned ...

The voracious growth of all cancers is powered by an alteration in cellular energy consumption. One characteristic of this is the production of a different version of the pyruvate kinase M gene, PK-M2 ...

Patricia F. Fitzpatrick Dimond Ph.D. Technical Editor of Clinical OMICs President of BioInsight Communications Some believe that the amount of time and money spent on the technology has made it ready ...

After a two-decade cycle of investor embrace and rejection, partnerships won and lost, failed clinical trials, layoffs, and rebuilds, Isis Pharmaceuticals has gained approval for the first ...

With so many companies working on multiple approaches to interrupting messenger RNA and, hence, protein production, it comes as no surprise that the intellectual property (IP) surrounding antisense is ...

Effective July, 2011, Antisense Pharma's founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company's strategy as a consultant.